Balancing the benefits and risks of a botulinum toxin vaccine

Expert Review of Vaccines

Volumn 6, Issue 6, 2007, Pages 883-886

  Simpson, Lance L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

BIOLOGICAL WARFARE; BLEPHAROSPASM; BOTULISM; DRUG EFFICACY; DRUG MECHANISM; DYSTONIA; EDITORIAL; HEADACHE; HEALTH HAZARD; HEMIFACIAL SPASM; HUMAN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SPASTICITY; STRABISMUS; TIC; TREMOR; VACCINATION;

ANIMALS; BACTERIAL VACCINES; BIOLOGICAL WARFARE AGENTS; BOTULINUM TOXINS; HUMANS; NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 37149033995     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.6.883     Document Type: Editorial

References (19)

1. Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285, 1059-1070 (2001).
2. Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193 (2004).
3. Comella CL, Simpson LL, Jankovic J. Botulinum toxins. Transformation of a toxin into a treatment. In: From Neuroscience to Neurology. Waxman S (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands 125-139 (2005).
4. Caya JC, Agni R, Miller JE. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med. 128, 653-662 (2004).
5. Sobel J. Botulism. Clin. Infect. Dis. 41(8), 1167-1173 (2005).
6. Jost WH. Botulinum toxin in painful diseases. In: Pain and Headache (Volume 14). Karger, Basel, Switzerland 174 (2003).
7. Felber ES. Botulinum toxin in primary care medicine. J. Am. Osteopath. Assoc. 106, 609-614 (2006).
8. Loder E, Biondi D. Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain 18, S169-S176 (2002).
9. Maksymowych AB, Simpson LL. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 273, 21950-21957 (1998).
10. Ahsan CR, Hajnoczky G, Maksymowych AB, Simpson LL. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 315, 1-8 (2005).
11. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
12. Jankovic J, Hallett M. Therapy with Botulinum Toxin. Marcel Dekker, NY, USA 608 (1994).
13. Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36, 1539-1548 (1998).
14. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 82, 955-966 (2000).
15. Maksymowych AB, Simpson LL. Structural features of the botulinum neurotoxin molecule that governs binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 310, 633-641 (2004).
16. Ravichandran E, Al-Saleem FH, Ancharski DM et al. A trivalent vaccine against botulinum toxin (serotypes A,B, and E) that can be administered by the mucosal route. Infect. Immun. 75, 3043-3054 (2007).
17. Mahmut N, Inoue K, Fujinaga Y et al. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component. J. Med. Microbiol. 51, 813-820 (2002).
18. Strayer MS, Maksymowych AB, Ruley KM et al. Adenovirus immunization against botulinum toxin. Neurotox. Res. 9, 243-248 (2006).
19. Zeng M, Xu Q, Elias MD et al. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 15(43), 7540-7548 (2007).